The significant EPS miss and rapidly escalating cash burn (R&D up 17x YoY) signal a high-risk pre-commercial stage. Monitor upcoming regulatory submissions for DMR-002 (H2 2026) and DMR-003 (2027), as these are the next catalysts. The strong cash runway limits near-term dilution risk, but the stock will likely trade on pipeline execution rather than financial results.
Price Chart
Executive Summary
Damora Therapeutics reported Q2 2026 EPS of -$0.62, a 67.6% miss versus consensus of -$0.37, driven by sharply higher R&D and G&A expenses as the company initiated its CLARITY-101 trial for DMR-001. The company holds $540.5M in cash, enough into H2 2029, but the wider-than-expected loss and pre-revenue status are bearish for a biotech with no approved products.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$0.62 missed consensus of -$0.37 by 67.6%
- Net loss widened to $31.2M from $3.4M YoY, driven by R&D spend of $25.5M (up from $1.5M)
- Cash position of $540.5M expected to fund operations into H2 2029
- Initiated Phase 1/1b CLARITY-101 trial for DMR-001 in mutCALR-driven ET and MF
- Preclinical data highlighted best-in-class potency and once-monthly dosing potential
- Appointed Dr. Andrew Cheng to the Board of Directors
Financial Impact
EPS miss of 67.6% vs consensus, net loss $31.2M vs $3.4M YoY; cash burn $21.9M in Q2 operating cash flow
Risk Factors
- No approved products or revenue, completely dependent on clinical trial success
- R&D and G&A expenses expected to remain elevated as trials expand
- EPS miss of 67.6% may erode investor confidence in management guidance
- Phase 1 data for DMR-001 not expected until mid-2027, leaving a long period without catalysts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342212 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 14d ago | Institutional Cluster | $20.26 | awaiting T+20 | — | $21.26 (+4.96%) |
Sep 28, 2026 28d ago | Insider Buy | $20.75 $21.26 | ▲ +2.46% | ▲ +2.49% | $21.26 (+2.46%) |
Aug 13, 2026 10w ago | EFFECT | $30.73 $28.10 | ▼ −8.56% | ▼ −6.81% | $21.26 (−30.82%) |
Aug 10, 2026 11w ago | Press Release | $30.36 $26.27 | ▲ +13.47% | ▲ +12.41% | $21.26 (+29.97%) |
Jul 20, 2026 14w ago | 8-K | $32.99 $31.80 | ▼ −3.61% | ▼ −6.17% | $21.26 (−35.56%) |
Apr 20, 2026 27w ago | 8-K | $26.82 $24.90 | ▼ −7.16% | ▼ −12.07% | $21.26 (−20.73%) |
Mar 23, 2026 31w ago | Press Release | $23.05 $26.82 | ▲ +16.36% | ▲ +8.94% | $21.26 (−7.77%) |
Mar 19, 2026 31w ago | Press Release | $18.14 $26.43 | ▲ +45.70% | ▲ +36.38% | $21.26 (+17.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers